Neil Kumar’s BridgeBio team locks in a $2.4B partnership as their next drug gets a snap review at the FDA

BridgeBio $BBIO is on a roll.

At the end of February, they won an approval for their first drug, a therapy used to treat …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neil Ku­mar’s Bridge­Bio team locks in a $2.4B part­ner­ship as their next drug gets a snap re­view at the FDA